IntroductionThe aim of this study is to conduct a meta-analysis to assess the efficacy of yttrium-90 selective internal radiation therapy (SIRT) in treating patients with breast cancer with hepatic metastasis.MethodPubMed and The Cochrane Library were queried from establishment to January 2021. The following keywords were implemented: “breast”, “yttrium”, and “radioembolization”. The following variables and outcomes were collected: publication year, region, sample size, study design, presence of extrahepatic disease, tumor burden, infused radioactivity, breast cancer subtype, previous treatment, median survival time (MST), length of follow-up, adverse events, and radiographical response such as Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).ResultsA total of 24 studies from 14 institutions were included in the present meta-analysis. On the basis of the data from 412 patients, post-embolization MST was 9.8 [95% confidence interval (CI): 9.0–11.6] months. Patients with additional extrahepatic metastasis had a poorer survival rate compared with those with localized hepatic metastasis only (MST: 5.3 vs. 15 months, p < 0.0001). Patients with <25% liver tumor burden exhibited more promising survival than those with >25% (MST: 10.5 vs. 6.8 months, p < 0.0139). On the basis of RECIST, mRECIST, and PERCIST criteria, tumor response rate was 36% (95% CI: 26%–47%), 49% (95% CI: 34%–65%), and 47% (95% CI: 17%–78%), respectively, whereas tumor control rate was 85% (95% CI: 76%–93%), 73% (95% CI: 59%–85%), and 97% (95% CI: 91%–100%), respectively.ConclusionOn the basis of the available published evidence, SIRT is feasible and effective in treating patients with breast cancer with liver metastasis. Patients with lower hepatic tumor burden and without extrahepatic metastasis demonstrated more survival benefit. Future randomized controlled trials are warranted.

No abstract

No abstract

supplemented at times by the sharp spoon or curette.Bosworth considers cauterization of the base of the tumor oftentimes harmful, stimulating the growth to renewed activity. This was apparently truo in the caBe just cited, for it was not until the galvano-cautery was abandoned that he made headway against the growth. For the same reason the galvano-cautery loop is not usually advisable. " The most serious obstacle met with in these operations, is always the excessive haemorrhage. This is probably true in all varieties of sarcoma, and especially so of the angiomatou8 growths. The source of the htemorrliage is always from the tumor itself, and the indications are to get the growth out as rapidly as possible, and to get down to its attachments. When this part is reached, the haemorrhage, as a rule, ceases at once."As I have already said, after the primary operation, the patient muBt be seen at specified intervals for at least two years, to watch for any tendency to recurrence. REFERENCES.

She had had four children, but no miscarriages. Two years before she had been very ill with "pelvic peritonitis," the cause of which was unknown. She had since been an invalid. Three months previous, she had increased trouble, followed by a discharge of pus from the bladder. Shortly before entrance she had been seen by Dr. J. W. Elliot, who advised her to come to the hospital. An examination at entrance showed a general matting together of the pelvic contents. There was also considerable fever. The patient's condition was very poor, and improved very little under a month's careful treatment.